Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Frederick National Laboratory for Cancer Research Resource Report Resource Website |
Frederick National Laboratory for Cancer Research (RRID:SCR_011245) | FNLCR | institution | United States federally funded research and development center supported by the National Cancer Institute and managed by the private contractor Leidos Biomedical Research. |
is parent organization of: AVIA is parent organization of: Cancer Imaging Archive (TCIA) |
Cancer | nlx_155984, Wikidata: Q28405614, grid.418021.e, ISNI: 0000 0004 0535 8394 | https://ror.org/03v6m3209 | SCR_011245 | Frederick National Laboratory, Frederick National Lab | 2026-09-03 04:50:58 | 0 | |||||||
|
Janssen Research and Development Resource Report Resource Website 1+ mentions |
Janssen Research and Development (RRID:SCR_003904) | Janssen R&D | commercial organization | Pharmaceutical company with a mission to discover and develop innovative medicines that ease patients'' suffering, and solve the most important unmet medical needs of our time. As one of the Janssen Pharmaceutical Companies, their strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. They leverage their world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas: cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, and oncology. | pharmaceutical, oncology, immunology, neuroscience, vaccine, medical |
is related to: Investigator Databank is related to: eTRIKS is related to: Predict-TB is related to: OncoTrack is related to: European Lead Factory is related to: EU-AIMS is related to: GetReal is related to: Kinetics for Drug Discovery is related to: MIP-DILI is related to: NEWMEDS is related to: ORBITO is related to: PharmaCog is related to: PREDECT is related to: Structural Genomics Consortium is related to: Open PHACTS is related to: EMIF is parent organization of: Investigator Databank |
Infectious disease, Cardiovascular disease, Metabolic disease, Immunological disorder, Cancer | nlx_158241 | SCR_003904 | Janssen Research & Development LLC, Janssen Research & Development | 2026-09-03 04:46:44 | 2 | |||||||
|
Althia Resource Report Resource Website |
Althia (RRID:SCR_003918) | Althia | commercial organization | A biomedical company in Spain focused on the development of new tools for diagnosis and personalized treatment of oncological diseases and precancerous. It has three areas of activity in permanent innovation: Assistance in Diagnosis / Prognosis in solid and hematological tumors, Translational Research covering the gap between basic and clinical research and advanced radiotherapy treatments based image-guided single dose (SD-IGRT). Their objectives are: * Provide an integrated tissue and tumor molecular phenotype analysis using the most advanced technologies in diagnosis, to guide the most appropriate treatment for each patient. * Discover and validate molecular patterns by molecular systems and platforms including pathology, to generate predictive algorithms through computational biology, evolution and determining the response of patients with a particular tumor profile. Althia has laboratories equipped with the most advanced equipment and technologies in Barcelona and Granada Genyo Center, with offices in Madrid. | oncology, diagnosis, prognosis, solid tumor, hematological tumor, translational, radiation, phenotype, analysis, pathology, hematology, hereditary | is related to: PRECISESADS | Cancer, Tumor, Solid tumor, Hematological tumor, Precancer | nlx_158279 | SCR_003918 | Althia Health Ltd., Althia Health, Advanced Laboratories of Translational Health, SL, S.L. | 2026-09-03 04:46:46 | 0 | |||||||
|
NYU Data Catalog Resource Report Resource Website |
NYU Data Catalog (RRID:SCR_004012) | NYU Data Catalog | catalog, data or information resource, database | A searchable data catalog that facilitates researchers'' access to large datasets available either publicly or through institutional or individual licensing. Dataset records include information about the content of the dataset, how to access the dataset, and local experts within NYULMC and NYU to assist in the use of these datasets. The data catalog will expand to include internally generated datasets from NYULMC and NYU in the near future. Use the contact form if you are interested in submitting a dataset to the data catalog. | data set, health, population, health care | Cancer, Chronic disease | The community can contribute to this resource | nlx_158439 | SCR_004012 | NYU Health Sciences Library Data Catalog | 2026-09-03 04:47:00 | 0 | |||||||
|
Experimental Pharmacology and Oncology Berlin-Buch Resource Report Resource Website 1+ mentions |
Experimental Pharmacology and Oncology Berlin-Buch (RRID:SCR_003954) | EPO | commercial organization | A small and medium-sized enterprise (SME) that has expertise in preclinical pharmacology, pharmacokinetics, and toxicology for the characterization of novel anticancer therapeutics and predictive biomarkers like: cytostatics, biologicals (peptides, antibodies), (anti)-hormones, immunomodulators (cytokines), and gene therapeutics. EPO has modern laboratories licensed for animal experiments and gene technology (S2) and a broad panel of murine and human tumor models growing in immunocompetent (SPF-quality, syngeneic strains) or immunodeficient mice (nude, SCID, NOD/SCID). EPO has established imaging technologies to monitor in vivo tumor growth. | tumor model, pharmaceutical, oncology, in vitro, in vivo, antitumor, preclinical, pharmacology, pharmacokinetics, toxicology, anticancer, therapeutic, biomarker, imaging, testing, validation, target | is related to: OncoTrack | Tumor, Cancer | nlx_158355 | SCR_003954 | EPO - Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology Berlin-Buch, Experimental Pharmacology & Oncology Berlin-Buch GmbH, EPO Berlin-Buch GmbH, EPO-GmbH | 2026-09-03 04:46:48 | 2 | |||||||
|
Alacris Theranostics Resource Report Resource Website |
Alacris Theranostics (RRID:SCR_003953) | Alacris | commercial organization | Commercial organization that uses next generation sequencing technologies coupled with computational modeling of tumor and somatic tissues in order to identify individualized therapies for cancer patients. The company also uses these technologies to help pharmaceutical partners stratify patients for their clinical trials. Alacris has an exclusive worldwide commercial license for the computational modeling of tumors and somatic tissues using proprietary computational systems modeling technologies ModCell developed at the Max Planck Institute for Molecular Genetics (MPI-MG) in Berlin coupled with next generation sequencing and genotyping technology developed at Harvard Medical School in Boston. The company also is building up the first next generation sequencing center in Europe for clinical operations. | next generation sequencing, computational modeling, clinical trial, somatic tissue, genotyping, genomics, oncogenomics, diagnostics, therapy, disease model, drug, personalized medicine, biomarker, drug development, tumor model, analysis, oncology | is related to: OncoTrack | Tumor, Cancer | nlx_158354, grid.473915.d | https://ror.org/04a0gnr15 | SCR_003953 | Alacris Theranostics GmbH | 2026-09-03 04:46:47 | 0 | ||||||
|
Big Ten Cancer Research Consortium Resource Report Resource Website |
Big Ten Cancer Research Consortium (RRID:SCR_004025) | BTCRC | consortium, data or information resource, organization portal, portal | A consortium that aims to transform cancer research through collaborative oncology trials that leverage the scientific and clinical expertise of the Big Ten universities. The goal is to align the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise. The clinical trials that will be developed will be linked to molecular diagnostics, enabling researchers to understand what drives the cancers to grow and what might be done to stop them from growing. The consortium also leverages geographical locations and existing relationships among the cancer centers. One of the consortium's goals is to harmonize contracts and scientific review processes to expedite clinical trials. The consortium will only focus on phase 0 to II trials because larger trials - even a randomized phase II trial - are difficult to conduct at a single cancer center. | oncology, drug development, basic research, clinical trial, clinical, genitourinary, gastrointestinal, thoracic, breast, nanotechnology, virus, triple-negative cell |
is affiliated with: Penn State Milton S. Hershey Medical Center; Pennsylvania; USA is affiliated with: University of Wisconsin-Madison; Wisconsin; USA is affiliated with: Rutgers University; New Jersey; USA is affiliated with: Northwestern University; Illinois; USA is affiliated with: University of Nebraska; Nebraska; USA is affiliated with: University of Minnesota Twin Cities; Minnesota; USA is affiliated with: Michigan State University; Michigan; USA is affiliated with: University of Michigan; Ann Arbor; USA is affiliated with: University of Iowa; Iowa; USA is affiliated with: Indiana University; Indiana; USA is affiliated with: University of Illinois College of Medicine; Illinois; USA has parent organization: Hoosier Cancer Research Network |
Cancer | Public | nlx_158452 | SCR_004025 | Big Ten CRC | 2026-09-03 04:46:49 | 0 | ||||||
|
Hoosier Cancer Research Network Resource Report Resource Website |
Hoosier Cancer Research Network (RRID:SCR_004026) | HCRN | nonprofit organization | An independent nonprofit cancer research organization that provides full-service clinical trial management and support, from conception and study design through project completion and publication. Established to explore and develop leading edge cancer treatments across the United States and internationally, their clinical trials, developed in collaboration with academic and community oncologists, are conducted within a member network of more than 130 clinical research sites. Their vision and mission is to form unparalleled relationships between academic, community, pharmaceutical, and biotech partners with the goal of advancing cancer research, education, and patient advocacy. There are no costs to become a member. | oncology, clinical trial, clinical | is parent organization of: Big Ten Cancer Research Consortium | Cancer | nlx_158453, Wikidata: Q30287333, grid.428706.f | https://ror.org/02mtpb511 | SCR_004026 | Hoosier Oncology Group | 2026-09-03 04:47:01 | 0 | ||||||
|
DanStem Resource Report Resource Website 1+ mentions |
DanStem (RRID:SCR_004021) | DanStem | data or information resource, portal, topical portal | Center consisting of 9 research groups who all address basic questions in stem cell and developmental biology with the overall aim of developing new stem cell-based therapeutic approaches for diabetes and cancer. DanStem comprises two sections: * The Novo Nordisk Foundation Section for Basic Stem Cell Biology (BasicStem) * The Section for Strategic Translational Stem Cell Research and Therapy (TransStem) DanStem was established as a result of a series of international recruitments coupled with internationally recognized research groups focused on insulin producing beta cells and cancer research already located at the University of Copenhagen. They all have well-established, international collaborations and actively participate in several international scientific consortia. DanStem is also active in training undergraduates, PhD students and postdocs. | stem cell, beta cell development, beta cell, insulin |
is related to: Beta Cell Biology Consortium has parent organization: University of Copenhagen; Copenhagen; Denmark |
Diabetes, Cancer | Novo Nordisk Foundation ; Danish Council for Strategic Research |
nlx_158446 | SCR_004021 | The Danish Stem Cell Center, Danish Stem Cell Center, DanStem - The Center for Stem Cell Research, Danish Center for Stem Cell Research | 2026-09-03 04:46:53 | 4 | ||||||
|
BC Cancer Agency Resource Report Resource Website 1+ mentions |
BC Cancer Agency (RRID:SCR_004201) | BCCA | institution | A portal that provides a province-wide, population-based cancer control program for the residents of British Columbia and the Yukon. The BC Cancer Agency''s mandate covers the spectrum of cancer care, from prevention and screening, to diagnosis, treatment, and through to rehabilitation. The BC Cancer Agency''s mandate is driven by a three-fold mission: 1. To reduce the incidence of cancer; 2. To reduce the mortality rate of people with cancer; 3. To improve the quality of life of people living with cancer. This mission drives everything we do, including providing screening, diagnosis and care, setting treatment standards, and conducting research into causes of, and cures for, cancer. The BC Cancer Agency operates five regional cancer centers, providing assessment and diagnostic services, chemotherapy, radiation therapy, and supportive care. Each of the BC Cancer Agency''s centers delivers cancer treatment based on provincial standards and guidelines established by the Agency. We work in partnership with communities to provide a network of chemotherapy clinics so patients can receive care closer to home. Research is an essential part of the BC Cancer Agency''s mission to not only find the causes of cancer, but to find better treatments for prolonged life and better quality of life. With direct links between the BC Cancer Agency''s physicians and researchers at our five centers, the Deeley Research Centre (located in Victoria) and the BC Cancer Agency''s Research Centre (located in Vancouver), we can quickly translate new discoveries into clinical applications. The BC Cancer Agency''s Research Centre includes eight specialty laboratories including the Genome Sciences Centre, and the Terry Fox Laboratory. The BC Cancer Foundation raises funds for cancer research and enhancements to care at the BC Cancer Agency. |
is related to: BC Cancer Foundation is parent organization of: cisRED: cis-regulatory element is parent organization of: British Columbia Gynaecologic Tissue Bank is parent organization of: British Columbia Tumour Tissue Repository is parent organization of: Spark is parent organization of: ALEA is parent organization of: APOLLOH is parent organization of: British Columbia Breast Cancer Tumour Bank is parent organization of: JointSNVMix is parent organization of: mutationSeq is parent organization of: Mouse Gene Expression at the BC Cancer Agency is parent organization of: C. elegans Resources is parent organization of: BCCA Cancer Drug Manual is parent organization of: flowCL is parent organization of: flowBin |
Cancer | BC Cancer Foundation | ISNI: 0000 0001 0702 3000, Wikidata: Q4835275, grid.248762.d, nlx_143635, Crossref funder ID: 501100005614 | https://ror.org/03sfybe47 | SCR_004201 | British Columbia Cancer Agency | 2026-09-03 04:47:13 | 3 | ||||||
|
CDP Resource Report Resource Website 10+ mentions |
CDP (RRID:SCR_004236) | CDP | data or information resource, funding resource, portal, topical portal | National program to improve the diagnosis and assessment of cancer by moving scientific knowledge into clinical practice by coordinating and funding resources and research for the development of innovative in vitro diagnostics, novel diagnostic technologies and appropriate human specimens. The Cancer Diagnosis Program is divided into four branches: Biorepository and Biospecimen Research Branch (BBRB), Diagnostic Biomarkers and Technology Branch (DBTB), Diagnostics Evaluation Branch (DEB), and the Pathology Investigation and Resources Branch (PIRB). | cancer research, cancer funding, cancer research funding |
is listed by: OMICtools has parent organization: DCTD |
Cancer | NCI | Available to cancer researchers | OMICS_01536 | SCR_004236 | Cancer Diagnosis Program | 2026-09-03 04:47:04 | 19 | |||||
|
Jackson Laboratory Resource Report Resource Website 10000+ mentions |
Jackson Laboratory (RRID:SCR_004633) | JAX | institution | An independent, nonprofit organization focused on mammalian genetics research to advance human health. Their mission is to discover the genetic basis for preventing, treating, and curing human disease, and to enable research for the global biomedical community. Jackson Laboratory breeds and manages colonies of mice as resources for other research institutions and laboratories, along with providing software and techniques. Jackson Lab also conducts genetic research and provides educational material for various educational levels. | genomic, disease, mouse model, human disease, biomaterial manufacture |
is listed by: One Mind Biospecimen Bank Listing is affiliated with: Integrative Human Microbiome Project is related to: ScienceExchange is related to: Federation of International Mouse Resources is related to: MGI strains is related to: One Mind Biospecimen Bank Listing is related to: Beta Cell Biology Consortium is related to: Mouse Mutagenesis Center for Developmental Defects is related to: GenomeMUSter is parent organization of: Mouse Models For Alzheimer's Disease Research is parent organization of: Type 1 Diabetes Resource is parent organization of: MouseCyc is parent organization of: Special Mouse Strains Resource is parent organization of: Gene Weaver is parent organization of: Mouse Phenome Database (MPD) is parent organization of: Jackson Laboratory Cytogenetic Models Resource is parent organization of: Parkinson's Disease Mouse Model Resource is parent organization of: Eye mutant resource - The Jackson Laboratory is parent organization of: Brainbow mouse resource at Jackson Labs is parent organization of: Short Course on the Genetics of Addiction is parent organization of: JAX Cre Repository is parent organization of: Donate a strain to The Jackson Laboratory Repository is parent organization of: Jackson Laboratory Neurobiology is parent organization of: QTL Archive is parent organization of: Mouse Genome Informatics: The Gene Ontology Project is parent organization of: Mouse Genome Informatics (MGI) is parent organization of: Mouse Tumor Biology Database is parent organization of: Gene Expression Database is parent organization of: The Jackson Laboratory Hearing Research Program is parent organization of: JAX Mice: Neural Tube Defects is parent organization of: JAX Neuroscience Mutagenesis Facility is parent organization of: Induced Mutant Resource is parent organization of: Mouse Mutant Resource is parent organization of: Mouse Genome Database is parent organization of: Mutant Mouse Resource and Research Center is parent organization of: eMouseAtlas is parent organization of: GBRS is parent organization of: Jackson Laboratory Scientific Instrument Services Core Facility provides: Knockout Mouse Project Repository |
Types 1 diabetes, Type 2 diabetes, Diabetes, Cardiovascular diseases, Metabolic disease, Cancer, Rare disease, Alzheimer's disease, Demantia | Available to the research community, Available to the educational community | ISNI: 0000 0004 0374 0039, nlx_63162, grid.249880.f, Crossref funder ID: 100005946 | https://ror.org/021sy4w91 | SCR_004633 | JAX Lab, Jackson Lab | 2026-09-03 04:47:15 | 15196 | |||||
|
Terry Fox Research Institute Resource Report Resource Website 1+ mentions |
Terry Fox Research Institute (RRID:SCR_011568) | TFRI | institution | Launched in October 2007, TFRI is the brainchild of the Terry Fox Foundation. TFRI involves collaboration between cancer hospitals and research organizations across Canada, and will occur initially in British Columbia, Alberta, Ontario and Quebec. TFRI will support translational cancer research projects with the potential to significantly improve the health of cancer patients. TFRI is organized into functionally integrated yet geographically dispersed nodes. Regional cancer hospitals and research organizations participate in each node by providing space for researchers and by arranging for the participation of cancer patients in research projects. At each node, two node co-ordinators provide leadership, and bring together local scientific and clinical research teams to propose and manage specific projects. The TFRI headquarters team liaises with the TFRI nodes and provides direction, co-ordination and facilitates communication across the entire organization. The Terry Fox Foundation has committed a minimum of $50 million (CAN) over five years from donations obtained during the 25th anniversary of the Terry Fox Marathon of Hope and from new funds anticipated and those raised since 2005. Other partners sharing the same vision are being sought who will be asked to commit additional resources to support the ongoing work of the TFRI. | has parent organization: Terry Fox Foundation | Cancer | grid.489333.6, nlx_149428 | https://ror.org/00mtf6c40 | SCR_011568 | 2026-09-03 04:51:23 | 3 | ||||||||
|
deCODE genetics Resource Report Resource Website 50+ mentions |
deCODE genetics (RRID:SCR_003334) | deCODE | commercial organization | A biopharmaceutical company applying its discoveries in human genetics to develop drugs and diagnostics for common diseases. They specialize in gene discovery - their population approach and resources have enabled them to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer. The company's genotyping capacity is now one of the highest in the world. They have a large population-based biobank containing whole blood and DNA samples with extensive relevant phenotypic information from around 120.000 Icelanders. In the company's work in more than 50 disease projects, their statistical and informatics departments have established themselves in data processing and analysis. deCODE genetics is widely recognized as a center of excellence in genetic research. | biopharmaceutical, genetics, drug, diagnostic, genotyping, phenotype, data processing, analysis, genetic variant, risk factor, genome, blood, dna, biobank, single nucleotide polymorphism |
is related to: EU-AIMS is related to: NEWMEDS |
Schizophrenia, Cardiovascular disease, Cancer, Type 2 diabetes, Atrial fibrillation, Heart attack | Free, Freely available | nif-0000-31959, ISNI: 0000 0004 0618 6889, grid.421812.c, Wikidata: Q493712 | https://ror.org/04dzdm737 | SCR_003334 | Islensk Erfdagreining EHF, Islensk Erfdagreining | 2026-09-03 04:46:16 | 67 | |||||
|
NCI Thesaurus Resource Report Resource Website 10+ mentions |
NCI Thesaurus (RRID:SCR_003563) | NCIt | controlled vocabulary, data or information resource, ontology | A reference terminology and core biomedical ontology for NCI that covers approximately 100,000 key biomedical concepts with terms, codes, definitions, and more than 200,000 inter-concept relationships. It is the reference terminology for NCI, NCI Metathesaurus and NCI informatics infrastructure covering vocabulary for clinical care, translational and basic research, and public information and administrative activities. It includes broad coverage of the cancer domain, including cancer related diseases, findings and abnormalities; anatomy; agents, drugs and chemicals; genes and gene products and so on. In certain areas, like cancer diseases and combination chemotherapies, it provides the most granular and consistent terminology available. It combines terminology from numerous cancer research related domains, and provides a way to integrate or link these kinds of information together through semantic relationships. NCIt features: * Stable, unique codes for biomedical concepts; * Preferred terms, synonyms, definitions, research codes, external source codes, and other information; * Links to NCI Metathesaurus and other information sources; * Over 200,000 cross-links between concepts, providing formal logic-based definition of many concepts; * Extensive content integrated from NCI and other partners, much available as separate NCIt subsets * Updated frequently by a team of subject matter experts. NCIt is a widely recognized standard for biomedical coding and reference, used by a broad variety of public and private partners both nationally and internationally including the Clinical Data Interchange Standards Consortium Terminology (CDISC), the U.S. Food and Drug Administration (FDA), the Federal Medication Terminologies (FMT), and the National Council for Prescription Drug Programs (NCPDP). | thesaurus, clinical, treatment, prevention, biomedical, owl, health, drug, chemotherapy |
is listed by: OBO is listed by: BioPortal is related to: NCI Metathesaurus is related to: OnEx - Ontology Evolution Explorer has parent organization: National Cancer Institute |
Cancer | See license, http://evs.nci.nih.gov/ftp1/NCI_Thesaurus/NCI_THESAURUS_license.txt | nlx_157698 | ftp://ftp1.nci.nih.gov/pub/cacore/EVS/, https://cabig.nci.nih.gov/concepts/EVS/, https://wiki.nci.nih.gov/display/EVS/NCI+Thesaurus+%28NCIt%29, http://nciterms.nci.nih.gov, http://purl.bioontology.org/ontology/NCIT | http://ncicb.nci.nih.gov/core/EVS | SCR_003563 | ncithesaurus | 2026-09-03 04:46:22 | 10 | ||||
|
canSAR Resource Report Resource Website 50+ mentions |
canSAR (RRID:SCR_006794) | canSAR | analysis service resource, data analysis service, data or information resource, database, production service resource, service resource | canSAR is an integrated database that brings together biological, chemical, pharmacological (and eventually clinical) data. Its goal is to integrate this data and make it accessible to cancer research scientists from multiple disciplines, in order to help with hypothesis generation in cancer research and support translational research. This cancer research and drug discovery resource was developed to utilize the growing publicly available biological annotation, chemical screening, RNA interference screening, expression, amplification and 3D structural data. Scientists can, in a single place, rapidly identify biological annotation of a target, its structural characterization, expression levels and protein interaction data, as well as suitable cell lines for experiments, potential tool compounds and similarity to known drug targets. canSAR has, from the outset, been completely use-case driven which has dramatically influenced the design of the back-end and the functionality provided through the interfaces. The Web interface provides flexible, multipoint entry into canSAR. This allows easy access to the multidisciplinary data within, including target and compound synopses, bioactivity views and expert tools for chemogenomic, expression and protein interaction network data. | molecular target, expression, cell line, compound, molecule, protein, structure, ligand, drug, 3d, genomics, 3d complex, bioactivity, protein affinity, cell line sensitivity, pathway, annotation, bio.tools, FASEB list |
is listed by: Debian is listed by: bio.tools is related to: Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) is related to: BindingDB is related to: Gene Ontology has parent organization: Cancer Research UK |
Cancer | Cancer Research UK C309/A8274 | PMID:22013161 | CanSAR is freely available to all cancer researchers. By using canSAR you are agreeing to the Terms of Use, Https://cansar.icr.ac.uk/cansar/terms-of-use/ | biotools:cansar, nlx_149410 | https://bio.tools/cansar | SCR_006794 | 2026-09-03 04:48:48 | 56 | ||||
|
Surveillance Epidemiology and End Results Resource Report Resource Website 5000+ mentions |
Surveillance Epidemiology and End Results (RRID:SCR_006902) | SEER | data or information resource, data set, database, narrative resource, report | SEER collects cancer incidence data from population-based cancer registries covering approximately 47.9 percent of the U.S. population. The SEER registries collect data on patient demographics, primary tumor site, tumor morphology, stage at diagnosis, and first course of treatment, and they follow up with patients for vital status.There are two data products available: SEER Research and SEER Research Plus. This was motivated because of concerns about the increasing risk of re-identifiability of individuals. The Research Plus databases require more rigorous process for access that includes user authentication through Institutional Account or multiple-step request process for Non-Institutional users. | cancer, statistics, epidemiology, registry, mortality, cancer mortality, african-american, hispanic, american-indian, alaska native, asian, hawaiian, pacific islander, demographic, tumor site, tumor morphology, stage, treatment, follow-up, vital status, FASEB list |
is listed by: re3data.org is related to: SEER*Stat is related to: NCI SEER Cancer Stage Variable Documentation is related to: SEER Datasets and Software is related to: NCI Division of Cancer Control and Population Sciences SEER-Medicare Comorbidity SAS Macros is related to: NCI Division of Cancer Control and Population Sciences SEER-Medicare Linked Data Resource has parent organization: National Cancer Institute |
Cancer, Leukemia | NCI | nif-0000-21366, r3d100010884 | SCR_006902 | Surveillance Epidemiology and End Results (SEER) Program, Surveillance Epidemiology End Results, Surveillance Epidemiology End Results (SEER) Program | 2026-09-03 04:48:59 | 6215 | ||||||
|
ARIAD Resource Report Resource Website 50+ mentions |
ARIAD (RRID:SCR_008559) | ARIAD | material service resource, production service resource, reagent manufacture, service resource | Cambridge, Massachusetts-based biotechnology company focused on cancer. Focus areas are blood cancers and solid tumors. Compounds: ponatinib, AP26113, ridaforolimus and AP1903., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | oncology, drug, therapy, treatment, drug development | uses: FluoroFinder | Cancer | THIS RESOURCE IS NO LONGER IN SERVICE | nif-0000-31436 | http://www.ariad.com/wt/page/regulation_kits | SCR_008559 | ARIAD Pharmaceuticals | 2026-09-03 04:49:49 | 55 | |||||
|
DrGaP Resource Report Resource Website 10+ mentions |
DrGaP (RRID:SCR_008670) | DrGaP | software resource | Designed to identify Driver Genes and Pathways in cancer genome sequencing studies. | is listed by: OMICtools | Cancer | OMICS_00149 | SCR_008670 | 2026-09-03 04:49:47 | 10 | |||||||||
|
OncoSNP Resource Report Resource Website 10+ mentions |
OncoSNP (RRID:SCR_012985) | OncoSNP | software resource | An analytical software tool for characterizing copy number alterations and loss-of-heterozygosity (LOH) events in cancer samples from SNP genotyping data. | is listed by: OMICtools | Cancer | Freely available for academic use, Non-commercial, Commercial with permission | OMICS_00728 | SCR_012985 | 2026-09-03 04:52:07 | 19 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the dkNET Resources search. From here you can search through a compilation of resources used by dkNET and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that dkNET has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on dkNET then you can log in from here to get additional features in dkNET such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into dkNET you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.